| Characteristic | Percentage of cancer immunotherapies |
|---|---|
| - | - |
| - | - |
| - | - |
| - | - |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Download
Source
Release date
June 2016
Region
Worldwide
Survey time period
as of May 2015
Number of respondents
522 companies that are currently developing at least one cancer immunotherapy product
Citation formats









